Natco Pharma today reported a 10.65 per cent rise in consolidated net profit at Rs 60.24 crore for the March quarter, driven by launch of Hepatitis C portfolio in the domestic market.
The company had posted a net profit of Rs 54.44 crore for the January-March period of the previous fiscal.
Net sales of the company rose to Rs 386.77 crore for the fourth quarter, as compared to Rs 190.57 crore for the same period of previous fiscal, Natco Pharma said in a regulatory filing.
"The key driver for the accelerated revenue growth was the company's Hepatitis C portfolio of products in the domestic Indian market," it added.
For the year ended March 31, the company posted a net profit of Rs 155.19 crore as compared to Rs 134.61 crore during the preceding fiscal.
Net sales for the year ended march 31, 2016 rose to Rs 1,088.35 crore as against Rs 774.20 crore in the 2014-15 fiscal.
Shares of Natco Pharma today closed 2.38 per cent up at Rs 463.05 apiece on BSE.
